Results 11 to 20 of about 318,160 (295)
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Controlling escape from angiogenesis inhibitors [PDF]
Nature Reviews Cancer, 2012 Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of chemotherapy and has beneficial effects on multiple advanced cancers, but response is often limited and the disease eventually progresses. Changes in the tumour microenvironment--hypoxia among them--that result from vascular pruning, suppressed angiogenesis and ...
Sennino, Barbara, McDonald, Donald M
openaire +6 more sources
Endogenous inhibitors of angiogenesis [PDF]
Journal of Cell Science, 2001 In the course of embryonic development, during some normal physiological processes in the adult, such as the female reproductive cycle, and also in a variety of pathologies, including tumour growth, new blood vessels develop from the pre-existing vascular network through endothelial cell sprouting,
Ruhrberg, C
core +5 more sources
An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis
Scientific Reports, 2023 Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar +5 more
doaj +1 more source
Cardiotoxic effects of angiogenesis inhibitors. [PDF]
Clin Sci (Lond), 2021 Abstract The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optimal cancer treatment in the ...
Dobbin SJH +4 more
europepmc +5 more sources
Journal of Dental Sciences, 2021 Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear.
Shin-ichi Yamada +8 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2021 Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced
HUANG Shifen, LING Xiaoling
doaj +1 more source
Oftalʹmologiâ, 2014 Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea ...
V. G. Likhvantseva +8 more
doaj +3 more sources
Pharmaceuticals, 2010 Angiogenesis is regulated by the local balance between angiogenesis stimulators and inhibitors. A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature.
Yasufumi Sato
doaj +1 more source
Acetylcholinesterase inhibitors attenuate angiogenesis [PDF]
Clinical Science, 2012 Donepezil {(RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one} is a reversible acetylcholinesterase inhibitor and used for treatment of patients with AD (Alzheimer's disease). Recent studies showed that treatment with donepezil reduced production of inflammatory cytokines in PBMCs (peripheral blood mononuclear cells).
Miyazaki, Ryohei +8 more
openaire +2 more sources